1. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis
- Author
-
Tadakazu Hisamatsu, Minoru Matsuura, and Jun Miyoshi
- Subjects
Moderate to severe ,business.industry ,medicine.drug_class ,Protein subunit ,Interleukin ,General Medicine ,Monoclonal antibody ,medicine.disease ,Ulcerative colitis ,Interleukin-12 ,Interleukin-23 ,Severity of Illness Index ,Immunology ,Ustekinumab ,Medicine ,Animals ,Humans ,Immunologic Factors ,Pharmacology (medical) ,Colitis, Ulcerative ,business ,Receptor ,Kappa ,medicine.drug - Abstract
Ustekinumab is a human IgG1 kappa monoclonal antibody that targets the p40 subunit of interleukin (IL)-12 and IL-23 and blocks the binding of these cytokines to the IL-12Rβ1 chain of their receptors. Ustekinumab is approved for treating moderate-to-severe ulcerative colitis (UC).We reviewed the mechanism of action, pharmacokinetics, efficacy, and safety of ustekinumab. Future challenges for optimizing UC treatment with ustekinumab are discussed.Ustekinumab has favorable clinical efficacy and safety profiles for moderately-to-severely active UC. Ustekinumab is the first biologic for targeting IL-12/IL-23 pathways. Therefore, ustekinumab can be a therapeutic option following the failure of other biologics, including anti-tumor necrosis factor-α antagonists and anti-α
- Published
- 2021